Document is current
Any future updates will be listed below
-
Authors
Delea, Thomas E. https://orcid.org/0000-0001-5493-1925
Ma, Qiufei
Kroog, Glenn S.
Ge, Wenzhen
Moynahan, Aaron
Sabater Anaya, Natalia
Rodriguez Lorenc, Karen
Song, Xue
-
Funding
Funding for this research was provided by:
Regeneron Pharmaceuticals, Inc.
- License Information
-
More Information
Article History
Received: 25 April 2024
Accepted: 27 June 2024
First Online: 4 August 2024
Declarations
:
: Thomas E. Delea, Aaron Moynahan, and Natalia Sabater Anaya are employed by Avalere Health, which has received research funding and consulting fees from Regeneron Pharmaceuticals, Inc. and Sanofi for research projects related to multiple myeloma. Qiufei Ma, Glenn S. Kroog, Wenzhen Ge, Karen Rodriguez Lorenc, and Xue Song are employees of, and own Regeneron stock or stock options in, Regeneron Pharmaceuticals, Inc.
: Use of the data was governed by a Data Use Agreement (DUA) from CMS (DUA number: RSCH-2022-58036). The study protocol was reviewed and approved by the Advarra institutional review board (IRB Organization number [IORG]: 0000635. Protocol number: Pro00057753). This study is in compliance with the Declaration of Helsinki of 1964 and its later amendments. This study has also been reviewed and approved by an ethics committee as part of the IRB review conducted by Advarra. Given this study used deidentified, retrospectively captured clinical data, participant consent was not required. The IRB granted a Waiver of Consent for this study. No identifiable information is included in the manuscript.
